The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of cetuximab in a real-life setting in France with respect to KRAS status: Preliminary results of EREBUS cohort study.
D. Smith
No relevant relationships to disclose
M. Rouyer
No relevant relationships to disclose
E. Francois
No relevant relationships to disclose
E. Mitry
No relevant relationships to disclose
A. Monnereau
No relevant relationships to disclose
A. Sa Cunha
No relevant relationships to disclose
E. Bignon
No relevant relationships to disclose
A. Le Monies
No relevant relationships to disclose
N. Moore
No relevant relationships to disclose
A. Fourrier-R├ęglat
No relevant relationships to disclose